Beijing Wantai Biological Pharmacy Enterprise Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Zhiming Jiang

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	3.6yrs

Actualizaciones recientes de la dirección

Recent updates

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) Analysts Are Reducing Their Forecasts For This Year

Jul 26

These 4 Measures Indicate That Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Is Using Debt Reasonably Well

Jul 22

Some Investors May Be Willing To Look Past Beijing Wantai Biological Pharmacy Enterprise's (SHSE:603392) Soft Earnings

Apr 04

Things Look Grim For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) After Today's Downgrade

Apr 02

Earnings Tell The Story For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) As Its Stock Soars 27%

Feb 28

CEO

Zhiming Jiang (51 yo)

less than a year

Permanencia

Ms. Zhiming Jiang is Managing Director and Director of Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. from 2024.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Tao Yu	Board Secretary	1.3yrs	CN¥1.09m	0.029% CN¥ 27.3m
Zhiming Jiang	MD & Director	less than a year	sin datos	sin datos
Yun Lu	Financial Director	less than a year	sin datos	sin datos

0.8yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 603392 no se considera experimentado ( 0.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Zhiming Jiang	MD & Director	less than a year	sin datos	sin datos
Zixin Qiu	Chairman	3.6yrs	CN¥2.05m	3.54% CN¥ 3.3b
Huiqiang Xing	Independent Director	3.8yrs	CN¥120.00k	sin datos

3.6yrs

Permanencia media

51yo

Promedio de edad

Junta con experiencia: La junta directiva de 603392 se considera experimentada (3.6 años de antigüedad promedio).

Beijing Wantai Biological Pharmacy Enterprise Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

No independent directors

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 26%

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) Analysts Are Reducing Their Forecasts For This Year

Price target decreased by 9.7% to CN¥63.10

Consensus revenue estimates fall by 15%

These 4 Measures Indicate That Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Is Using Debt Reasonably Well

Consensus EPS estimates increase by 16%, revenue downgraded

Price target decreased by 7.1% to CN¥69.85

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Consensus EPS estimates fall by 26%

First quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.99 in 1Q 2023)

Investor sentiment improves as stock rises 15%

Some Investors May Be Willing To Look Past Beijing Wantai Biological Pharmacy Enterprise's (SHSE:603392) Soft Earnings

Consensus revenue estimates fall by 52%

Things Look Grim For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) After Today's Downgrade

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Earnings Tell The Story For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) As Its Stock Soars 27%

Investor sentiment deteriorates as stock falls 15%

Price target increased by 11% to CN¥69.43

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Investor sentiment improves as stock rises 24%

Consensus revenue estimates decrease by 35%

Third quarter 2023 earnings released: EPS: CN¥0.085 (vs CN¥0.99 in 3Q 2022)

Price target decreased by 19% to CN¥78.50

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) announces an Equity Buyback for CNY 400 million worth of its shares.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 10% to CN¥97.50

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥1.38 (vs CN¥0.39 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.55 (vs CN¥0.79 in 2Q 2021)

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) announces an Equity Buyback for CNY 400 million worth of its shares.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

No independent directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.38 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥1.15 (vs CN¥0.29 in 2Q 2020)

Consensus forecasts updated

Price target increased to CN¥339

First quarter 2021 earnings released: EPS CN¥0.67 (vs CN¥0.18 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.62 (vs CN¥0.54 in FY 2019)

Full year 2020 earnings released: EPS CN¥1.62 (vs CN¥0.54 in FY 2019)

Revenue and earnings beat expectations

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥338

New 90-day high: CN¥290

New 90-day high: CN¥221

New 90-day low: CN¥171

Third quarter earnings released

New 90-day low: CN¥173

First half earnings released

New 90-day high - CN¥243

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. to Report First Half, 2020 Results on Aug 21, 2020

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad